These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 30707899)

  • 1. Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma.
    Kuonen F; Huskey NE; Shankar G; Jaju P; Whitson RJ; Rieger KE; Atwood SX; Sarin KY; Oro AE
    J Invest Dermatol; 2019 Jul; 139(7):1439-1448. PubMed ID: 30707899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
    Danhof R; Lewis K; Brown M
    Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the hedgehog pathway to treat basal cell carcinoma.
    Geeraert P; Williams JS; Brownell I
    J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquisition of Drug Resistance in Basal Cell Nevus Syndrome Tumors through Basal to Squamous Cell Carcinoma Transition.
    Jussila AR; Haensel D; Gaddam S; Oro AE
    J Invest Dermatol; 2024 Jun; 144(6):1368-1377.e6. PubMed ID: 38157930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. INTU is essential for oncogenic Hh signaling through regulating primary cilia formation in basal cell carcinoma.
    Yang N; Leung EL; Liu C; Li L; Eguether T; Jun Yao XJ; Jones EC; Norris DA; Liu A; Clark RA; Roop DR; Pazour GJ; Shroyer KR; Chen J
    Oncogene; 2017 Aug; 36(35):4997-5005. PubMed ID: 28459465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.
    Piérard-Franchimont C; Hermanns-Lê T; Paquet P; Herfs M; Delvenne P; Piérard GE
    Future Oncol; 2015 Nov; 11(22):2997-3002. PubMed ID: 26437034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elucidating the role of molecular signaling pathways in the tumorigenesis of basal cell carcinoma.
    Tang JY
    Semin Cutan Med Surg; 2011 Dec; 30(4 Suppl):S6-9. PubMed ID: 22177103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas.
    Wahid M; Jawed A; Mandal RK; Dar SA; Khan S; Akhter N; Haque S
    Crit Rev Oncol Hematol; 2016 Feb; 98():235-41. PubMed ID: 26614022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma.
    Otsuka A; Dreier J; Cheng PF; Nägeli M; Lehmann H; Felderer L; Frew IJ; Matsushita S; Levesque MP; Dummer R
    Clin Cancer Res; 2015 Mar; 21(6):1289-97. PubMed ID: 25593302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hedgehog signaling in basal cell carcinoma.
    Otsuka A; Levesque MP; Dummer R; Kabashima K
    J Dermatol Sci; 2015 May; 78(2):95-100. PubMed ID: 25766766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.
    Zhao X; Ponomaryov T; Ornell KJ; Zhou P; Dabral SK; Pak E; Li W; Atwood SX; Whitson RJ; Chang AL; Li J; Oro AE; Chan JA; Kelleher JF; Segal RA
    Cancer Res; 2015 Sep; 75(17):3623-35. PubMed ID: 26130651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basal cell carcinoma and the carcinogenic role of aberrant Hedgehog signaling.
    Saran A
    Future Oncol; 2010 Jun; 6(6):1003-14. PubMed ID: 20528237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smoothened variants explain the majority of drug resistance in basal cell carcinoma.
    Atwood SX; Sarin KY; Whitson RJ; Li JR; Kim G; Rezaee M; Ally MS; Kim J; Yao C; Chang AL; Oro AE; Tang JY
    Cancer Cell; 2015 Mar; 27(3):342-53. PubMed ID: 25759020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hedgehog Pathway Inhibition.
    Sekulic A; Von Hoff D
    Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib.
    Hehlgans S; Booms P; Güllülü Ö; Sader R; Rödel C; Balermpas P; Rödel F; Ghanaati S
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient with Gorlin syndrome and metastatic basal cell carcinoma refractory to smoothened inhibitors.
    Zhu GA; Li AS; Chang AL
    JAMA Dermatol; 2014 Aug; 150(8):877-9. PubMed ID: 24898076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basal cell carcinomas: attack of the hedgehog.
    Epstein EH
    Nat Rev Cancer; 2008 Oct; 8(10):743-54. PubMed ID: 18813320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
    Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
    Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Not Available].
    Basset-Seguin N
    Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of hedgehog and vitamin D signaling pathways in basal cell carcinomas.
    Albert B; Hahn H
    Adv Exp Med Biol; 2014; 810():329-41. PubMed ID: 25207374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.